Introduction
============

In recent years, the role for inflammation in tumorigenesis has become more evident. Chronic inflammation, not only facilitates the progression of normal cells to malignancy but also, supports survival of many malignancies through production of proinflammatory cytokines.[@b1-ott-7-2067],[@b2-ott-7-2067] Through activation of various downstream effectors, cytokines control the immune and inflammatory milieu to either favor antitumor immunity or enhance tumor progression, and also, have direct effects on cancer cell growth and survival.[@b3-ott-7-2067],[@b4-ott-7-2067]

Interleukin-1 (IL-1) is a pleiotrophic cytokine that primarily affects inflammatory responses, immune reactivity, and hematopoiesis.[@b5-ott-7-2067],[@b6-ott-7-2067] Accumulating evidence has shown that IL-1 is involved in all phases of the malignant process, such as tumorigenesis, tumor invasiveness and progression, as well as activation/suppression of antitumor immunity. The IL-1 cytokine family consists of three members, IL-1α, IL-1β, and IL-1 receptor (IL-1R) antagonist.[@b7-ott-7-2067] In particular, IL-1α has been suggested to regulate cancer cell invasion and metastasis, inducing invasiveness-promoting factors (ie, matrix metalloproteinases) and adhesion molecules.[@b8-ott-7-2067],[@b9-ott-7-2067] In animal models, mice solely deficient in IL-1α exhibit dramatically impaired tumor development and blood vessel growth.[@b10-ott-7-2067] IL-1α expression has also been found in pancreatic adenocarcinoma,[@b11-ott-7-2067] colon cancer,[@b12-ott-7-2067] gastric carcinoma,[@b13-ott-7-2067] thyroid carcinoma,[@b14-ott-7-2067] ovarian carcinoma,[@b15-ott-7-2067] lung carcinoma,[@b16-ott-7-2067] and adult T-cell leukemia.[@b17-ott-7-2067] Wolf et al reported that IL-1α contributes to the transcriptional activation of nuclear factor kappaB (NF-κB) and activator protein 1 (AP-1), and promotes cell survival and growth in the head and neck squamous cell carcinoma cell line.[@b18-ott-7-2067] Xu et al revealed that autocrine IL-1α and paracrine hepatocyte growth factor (HGF) coenhance the metastatic potential of pancreatic cancer cells via both IL-1α and HGF signaling pathways.[@b19-ott-7-2067] Therefore, IL-1α may be involved in tumor progression.

The gene encoding IL-1α is located in chromosome 2q13-21, and there is a single nucleotide polymorphism (SNP) at position -889.[@b20-ott-7-2067] *IL-1α* -889 C/T polymorphism has been reported to be associated with an increased cytokine production.[@b21-ott-7-2067],[@b22-ott-7-2067] To date, many studies have been published to assess the association between *IL-1α* -889 C/T polymorphism and cancer susceptibility, but they reported controversial results. A single case-control study may fail to completely demonstrate the complicated genetic relationship because of the small sample size.[@b23-ott-7-2067] In order to provide strong evidence of the effects of *IL-1α* -889 C/T polymorphism on cancer susceptibility, we performed a meta-analysis by combining data from numerous published studies.

Methods
=======

Search strategy
---------------

A literature search in PubMed, Embase™, Web of Science™, Science Direct^®^, SpringerLink, EBSCO, Wanfang, and Chinese National Knowledge Infrastructure (CNKI) databases was carried out to identify studies investigating the association between cancer risk and *IL-1α* -889 C/T polymorphism, without language, time period, or sample size limitations, and covering all papers published up to May 2014. The sets of search terms were as follows: "IL-1, or IL-1α, or IL-1alpha, or interleukin-1A, or IL-1A" and "cancer, or carcinoma, or tumor, or neoplasma" and "polymorphism, or variant, or SNP".

### Inclusion and exclusion criteria

The selection criteria of the retrieved articles in our meta-analysis were as follows: a) case--control studies or cohort studies; b) studies evaluating the association between *IL-1α -*889 C/T polymorphism and cancer risk; c) identification of cancer patients was confirmed histologically or pathologically; and d) sufficient data available to calculate an odds ratio (OR) with 95% confidence interval (CI). The exclusion criteria of the meta-analysis were: a) case-only studies; b) studies with incomplete data; and c) meta-analyses, letters, reviews, and editorial articles. If more than one study was published by the same author using the same patient population or overlapping case series, the study with the largest size of samples was included.

### Data extraction

The following data from included studies were extracted independently by two authors (Cheng and Hao). The following data were collected: name of first author; year of publication; country; ethnicity; cancer types; sources of control; number of cases and controls, and genotype frequency in cases and controls; genotyping methods; *P* value for Hardy--Weinberg equilibrium; and minor allele frequency. Any disagreement was resolved through discussions by these two authors until consensus was reached.

### Sensitivity analysis

Sensitivity analysis was performed by excluding each investigation individually and recalculating the pooled estimates and their corresponding 95% CIs to determine the effect of each study on the summary estimate.

### Statistical analysis

The strength of the association between *IL-1α* -889 C/T polymorphism and cancer risk was estimated by calculating ORs with 95% CIs, based on the genotype frequencies in cases and controls. The pooled ORs were calculated for five models: allele model (T allele vs C allele), dominant model (TT+TC vs CC), recessive model (TT vs TC+CC), homozygous comparison (TT vs CC), and heterozygous comparison (TC vs CC). The chi square-based *Q* statistic test was employed to test between-study heterogeneity, and heterogeneity was considered significant when *P*\<0.1 for the *Q* statistic. The fixed effect model was chosen when studies were homogeneous (with *P*\>0.10 for the *Q* test); otherwise, a random effects model was adopted. The significance of the pooled OR was determined by *Z* test, and *P*-value less than 0.05 was considered as statistically significant. Subgroup analyses were carried out to explore the source of heterogeneity among variables, including ethnicity and source of control, respectively. Publication bias was both examined with Begg's funnel plot[@b24-ott-7-2067] and Egger's regression method[@b25-ott-7-2067] (*P*\<0.05 was considered representative of statistically significant publication bias). All statistics were conducted by using Stata Statistical Software: Release 11.0 (StataCorp, College Station, TX, USA).

Results
=======

Characteristic of eligible studies
----------------------------------

The detailed screening process is shown in [Figure 1](#f1-ott-7-2067){ref-type="fig"}. A total of 311 publications from all databases were reviewed. After a review of titles, abstracts, and articles, 20 studies, with 6,782 cases and 7,767 controls, were included in this meta-analysis.[@b20-ott-7-2067]--[@b22-ott-7-2067],[@b26-ott-7-2067]--[@b42-ott-7-2067] [Table 1](#t1-ott-7-2067){ref-type="table"} lists the studies identified and their main characteristics. There were six studies conducted in Asian populations, ten studies in Caucasian populations, and four studies in mixed populations. Population-based controls were performed in eleven studies, and hospital-based controls in nine studies. The genotype distribution of *IL-1α* -899 C/T polymorphism in the controls was in compliance with Hardy--Weinberg equilibrium, except for in three studies.[@b22-ott-7-2067],[@b26-ott-7-2067],[@b33-ott-7-2067]

### Meta-analysis results

The main results of the meta-analysis of the association between *IL-1α* -889 C/T polymorphism and cancer risk are shown in [Table 2](#t2-ott-7-2067){ref-type="table"}. In the overall analysis, there was significant association between *IL-1α* -889 C/T polymorphism and cancer risk under an allele model (OR =1.12, 95% CI =1.02--1.24, *P*=0.02), recessive model (OR =1.34, 95% CI =1.06--1.68, *P*=0.01), and homozygous comparison (OR =1.38, 95% CI =1.10--1.74, *P*,0.01), but no significant association was found under other models.

Subgroup analysis by ethnicity and source of controls was performed in order to determine the source of heterogeneity among the studies and to assess the effect of ethnicity and source of controls on the association between *IL-1α* -889 C/T polymorphism and cancer risk. Then, stratified analysis by ethnicity showed that a statistically increased cancer risk was found in the Asian population under a recessive model (OR =2.57, 95% CI =1.11--5.98, *P*=0.03) and homozygous comparison (OR =2.60, 95% CI =1.12--6.04, *P*=0.03), but there was no significant association between cancer risk and *IL-1α* -889 C/T in either the Caucasian or mixed population ([Table 2](#t2-ott-7-2067){ref-type="table"}, [Figure 2](#f2-ott-7-2067){ref-type="fig"}). Moreover, a subgroup analysis was conducted by source of control, and a statistically increased cancer risk was found in the hospital-based group, under a recessive model (OR =1.62, 95% CI =1.03--2.56, *P*=0.04) and homozygous comparison (OR =1.67, 95% CI =1.04--2.68, *P*=0.03) ([Table 2](#t2-ott-7-2067){ref-type="table"}, [Figure 3](#f3-ott-7-2067){ref-type="fig"}).

### Sensitivity analysis

Sensitivity analysis was performed to evaluate the stability of the meta-analysis. Statistically similar data were obtained after sequentially excluding each study, indicating that our results were statistically reliable.

### Publication bias

Begg's funnel plot and Egger's test were performed to assess the publication bias of studies. The shape of Begg's funnel plot was symmetrical ([Figure 4](#f4-ott-7-2067){ref-type="fig"}). The statistical results still did not show publication bias by Egger's test (*P*=0.923).

Discussion
==========

Cytokines might contribute to tumor development by enhancing angiogenesis and tumor cell adhesions or by interfering with the antitumoral mechanisms of the immune system.[@b43-ott-7-2067] In recent years, studies have demonstrated that carcinogenesis is associated with altered levels of inflammatory cytokines, which have a substantial impact on numerous biological activities. Common variation in cytokine genes could lead to variation in protein structure, thus affecting the quantity and activity of cytokines.[@b20-ott-7-2067],[@b44-ott-7-2067] Knowledge of the genetic variations that influence cancer development is important for assessing cancer risk and identifying preventive strategies.

IL-1α, an important proinflammatory cytokine, plays an important role in tumorigenesis and development.[@b45-ott-7-2067] IL-1α has been reported to be produced by cancer cell lines derived from carcinomas of the pancreas, lung, ovary, colon, and stomach.[@b19-ott-7-2067] Of note, some data suggest that IL-1α is less important in carcinogenesis and tumor invasion than IL-1β. Membrane-associated IL-1α seems to increase antitumor immunity and subsequently might contribute to tumor cell eradication.[@b46-ott-7-2067] Cancer is considered to be a complex and multistep disease that results from interactions between environmental and genetic factors,[@b47-ott-7-2067] and SNPs are associated with intersubject variation and diversity, and have been recently considered as important genetic factors involved in the development of cancer. Several polymorphisms have been described in *IL-1α* genes, which probably modulate IL-1α protein production and have been related with the development and severity of cancer.[@b26-ott-7-2067],[@b48-ott-7-2067] The most common polymorphism, -889 C/T polymorphism, has been associated with high production of IL-1α.[@b22-ott-7-2067],[@b49-ott-7-2067] To date, many studies have investigated the role of the *IL-1α* -889 C/T polymorphism in different types of cancer. However, the results of these studies remain inconclusive. We, therefore, performed a meta-analysis by pooling 20 eligible studies, including 6,782 cases and 7,767 controls, to clarify this inconsistency and to achieve a more precise estimation of the relationship between *IL-1α* -889 C/T polymorphism and cancer risk. Our results demonstrated that *IL-1α* -889 C/T polymorphism was significantly associated with increased overall cancer risk under an allele model (*P*=0.02), recessive model (*P*=0.01), and homozygous comparison (*P*\<0.01).

In order to explore a potential source of heterogeneity, we also performed subgroup analysis based on ethnicity. We found the significant association of *IL-1α* -889 C/T polymorphism with cancer risk only in the Asian population, under a recessive model (*P*=0.03) and homozygous comparison (*P*=0.03). Our results also revealed that no statistically significant risk was observed in Caucasian and mixed populations, under all genetic models. Moreover, in the subgroup analysis by source of control, we found a statistically increased cancer risk in the hospital-based group, under a recessive model (*P*=0.04) and homozygous comparison (*P*=0.03), but not in the population-based group. Hospital-based controls were randomly selected cancer-free patients from the same hospital as the cancer patients during the same period, and they might be from a related disease population and not the general population. Selection bias could not be avoided.

The findings in this meta-analysis should be interpreted with caution because of several limitations. First, in the subgroup analysis by ethnicity, the included studies were mainly in Asians and Caucasians, and future study should evaluate the association between *IL-1*α -889 C/T polymorphism and cancer risk in different ethnicities, especially in Africans. Second, the meta-analysis was limited by a relatively small number of available studies. It is difficult to perform subgroup analysis for every type of cancer. Third, only published studies in the selected databases were included in this meta-analysis. It is possible that some studies that were not included in these databases or some unpublished studies with null results were not identified, and this may have biased our results. Fourth, gene--gene and gene--environment interactions may play important roles in the function of *IL-1α* -889C/T polymorphism, but the effect was not addressed in our meta-analysis, due to unavailable data.

Conclusion
==========

To the best of our knowledge, this is the first meta-analysis to assess the relationship between *IL-1α* -889 C/T polymorphism and cancer risk. Our results demonstrated that *IL-1α* -889 C/T polymorphism was associated with increased risk of cancer. Further stratification by ethnicity or source of control indicated that the association between *IL-1α* -889 C/T polymorphism and cancer was restricted to the Asian population and the hospital-based group. More studies with large sample size are needed to further assess the associations described above.
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###### 

Characteristics of the eligible studies included in the meta-analysis

  Studies                                     Year   Country                      Ethnicity   Cancer type      Source of controls   Sample size   Genotyping method      HWE (controls)   MAF (controls)
  ------------------------------------------- ------ ---------------------------- ----------- ---------------- -------------------- ------------- ---------------------- ---------------- ----------------
  Abazis-Stamboulieh et al[@b26-ott-7-2067]   2007   Greece                       Caucasian   Myeloma          PB                   74/160        PCR-RFLP               \<0.01           0.213
  Ioana Braicu[@b20-ott-7-2067]               2007   Germany                      Caucasian   Ovarian          HB                   147/129       Pyrosequencing         0.565            0.283
  Bushley et al[@b27-ott-7-2067]              2004   USA                          Mixed       Ovarian          PB                   178/216       PCR-sequencing         0.687            0.169
  Foster et al[@b28-ott-7-2067]               2000   USA                          Mixed       Sarcoma          HB                   111/123       PCR-sequencing         0.393            0.272
  Ennas et al[@b29-ott-7-2067]                2008   Italy                        Caucasian   Leukemia         PB                   40/111        Taqman^®^              0.835            0.261
  Eshghyar et al[@b30-ott-7-2067]             2012   Iran                         Asian       KCOT             PB                   30/145        PCR-SSP                0.541            0.317
  Grimm et al[@b22-ott-7-2067]                2004   Austria                      Caucasian   Vulvar           HB                   68/228        Pyrosequencing         0.008            0.307
  Grimm et al[@b31-ott-7-2067]                2011   Austria                      Caucasian   Cervical         HB                   131/204       Pyrosequencing         0.532            0.314
  Wang[@b32-ott-7-2067]                       2005   People's Republic of China   Asian       Cervical         PB                   50/50         PCR                    0.408            0.300
  Hefler et al[@b33-ott-7-2067]               2005   Germany                      Caucasian   Breast           PB                   269/227       Pyrosequencing         0.012            0.304
  Hoeft et al[@b34-ott-7-2067]                2008   Germany                      Caucasian   Lymphoma         PB                   650/659       PCR-RFLP               0.557            0.284
  Hou et al[@b35-ott-7-2067]                  2007   Poland                       Caucasian   Gastric          PB                   304/417       PCR-sequencing         0.090            0.350
  Rothman et al[@b36-ott-7-2067]              2006   Mixed                        Mixed       NHL              PB                   3053/3457     N/A                    0.524            0.289
  Saenz-Lopez et al[@b37-ott-7-2067]          2008   Spain                        Caucasian   Prostate         PB                   297/311       PCR-sequencing         0.533            0.297
  Senguven and Oygur[@b21-ott-7-2067]         2011   Turkey                       Caucasian   KCOT             HB                   74/30         PCR-RFLP               0.258            0.300
  Snoussi et al[@b38-ott-7-2067]              2005   Tunisia                      Mixed       Breast           PB                   305/200       PCR-RFLP               0.066            0.380
  Yang et al[@b39-ott-7-2067]                 2011   People's Republic of China   Asian       Nasopharyngeal   HB                   248/296       PCR-RFLP               0.401            0.265
  Zheng et al[@b40-ott-7-2067]                2013   People's Republic of China   Asian       Esophageal       HB                   366/370       SNPlex^®^ genotyping   0.579            0.104
  Bai et al[@b41-ott-7-2067]                  2013   People's Republic of China   Asian       Lung             HB                   193/211       Taqman                 0.117            0.097
  Qu et al[@b42-ott-7-2067]                   2014   People's Republic of China   Asian       Nasopharyngeal   HB                   194/231       Taqman                 0.961            0.113

**Abbreviations:** HB, hospital-based controls; HWE, Hardy--Weinberg equilibrium; KCOT, keratocystic odontogenic tumor; MAF: minor allele frequency; N/A, not available; NHL, non-Hodgkin's lymphoma; PB, population-based controls; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism; SSP, sequence-specific primers.

###### 

Overall and subgroup estimates of the associations of *IL-1α* -899 C/T polymorphism with cancer risk under all models.

                      T allele vs C allele Allele model   TT+TC vs CC Dominant model   TT vs TC+CC Recessive model   TT vs CC Homozygous comparison   TC vs CC Heterozygous comparison                                                           
  ------------------- ----------------------------------- ---------------------------- ----------------------------- -------------------------------- ---------------------------------- ------ ------------------- -------- ------------------- ------
  Overall             1.12 (1.02--1.24)                   0.02                         1.12 (0.98--1.27)             0.10                             1.34 (1.06--1.68)                  0.01   1.38 (1.10--1.74)   \<0.01   1.07 (0.92--1.24)   0.41
  Ethnicity                                                                                                                                                                                                                                      
   Caucasian          1.07 (0.98--1.17)                   0.15                         1.19 (0.95--1.50)             0.14                             1.10 (0.90--1.34)                  0.37   1.14 (0.92--1.41)   0.22     1.21 (0.90--1.60)   0.20
   Asian              1.34 (0.95--1.90)                   0.10                         1.12 (0.86--1.48)             0.40                             2.57 (1.11--5.98)                  0.03   2.60 (1.12--6.04)   0.03     0.93 (0.76--1.15)   0.51
   Mixed              1.04 (0.97--1.11)                   0.32                         1.02 (0.80--1.29)             0.87                             1.04 (0.88--1.22)                  0.67   1.07 (0.90--1.26)   0.44     1.01 (0.78--1.31)   0.96
  Source of control                                                                                                                                                                                                                              
   PB                 1.09 (0.97--1.22)                   0.14                         1.15 (0.95--1.40)             0.15                             1.17 (0.92--1.50)                  0.20   1.10 (0.96--1.27)   0.15     1.14 (0.90--1.44)   0.28
   HB                 1.16 (0.97--1.39)                   0.11                         1.09 (0.94--1.27)             0.27                             1.62 (1.03--2.56)                  0.04   1.67 (1.04--2.68)   0.03     0.99 (0.84--1.17)   0.95

**Abbreviations:** CI, confidence interval; HB, hospital-based control; IL, interleukin; PB, population-based control; OR, odds ratio; vs, versus.
